These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 33569615)
1. Spatiotemporal habitats from multiparametric physiologic MRI distinguish tumor progression from treatment-related change in post-treatment glioblastoma. Kim M; Park JE; Kim HS; Kim N; Park SY; Kim YH; Kim JH Eur Radiol; 2021 Aug; 31(8):6374-6383. PubMed ID: 33569615 [TBL] [Abstract][Full Text] [Related]
2. Low conductivity on electrical properties tomography demonstrates unique tumor habitats indicating progression in glioblastoma. Park JE; Kim HS; Kim N; Kim YH; Kim JH; Kim E; Hwang J; Katscher U Eur Radiol; 2021 Sep; 31(9):6655-6665. PubMed ID: 33880619 [TBL] [Abstract][Full Text] [Related]
3. Spatiotemporal Heterogeneity in Multiparametric Physiologic MRI Is Associated with Patient Outcomes in IDH-Wildtype Glioblastoma. Park JE; Kim HS; Kim N; Park SY; Kim YH; Kim JH Clin Cancer Res; 2021 Jan; 27(1):237-245. PubMed ID: 33028594 [TBL] [Abstract][Full Text] [Related]
4. Prospective longitudinal analysis of imaging-based spatiotemporal tumor habitats in glioblastoma, IDH-wild type: implication in patient outcome using multiparametric physiologic MRI. Moon HH; Park JE; Kim N; Kim YH; Song SW; Hong CK; Kim JH; Kim HS BMC Cancer; 2024 Sep; 24(1):1197. PubMed ID: 39334005 [TBL] [Abstract][Full Text] [Related]
5. Tumor habitat analysis by magnetic resonance imaging distinguishes tumor progression from radiation necrosis in brain metastases after stereotactic radiosurgery. Lee DH; Park JE; Kim N; Park SY; Kim YH; Cho YH; Kim HS Eur Radiol; 2022 Jan; 32(1):497-507. PubMed ID: 34357451 [TBL] [Abstract][Full Text] [Related]
6. Prediction of pseudoprogression in post-treatment glioblastoma using dynamic susceptibility contrast-derived oxygenation and microvascular transit time heterogeneity measures. Park JE; Kim HS; Kim N; Borra R; Mouridsen K; Hansen MB; Kim YH; Hong CK; Kim JH Eur Radiol; 2024 May; 34(5):3061-3073. PubMed ID: 37848773 [TBL] [Abstract][Full Text] [Related]
7. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients. Kim JY; Park JE; Jo Y; Shim WH; Nam SJ; Kim JH; Yoo RE; Choi SH; Kim HS Neuro Oncol; 2019 Feb; 21(3):404-414. PubMed ID: 30107606 [TBL] [Abstract][Full Text] [Related]
8. Mapping Tumor Habitats in IDH-Wild Type Glioblastoma: Integrating MR Imaging, Pathologic, and RNA Data from Ivy Glioblastoma Atlas Project. Park JE; Oh JY; Park DH; Lee HS; Yoon S; Kim NY; Park SY; Song SW; Kim YH; Hong CK; Kim JH; Kim HS Neuro Oncol; 2024 Aug; ():. PubMed ID: 39177498 [TBL] [Abstract][Full Text] [Related]
9. Tumor Habitat Analysis Using Longitudinal Physiological MRI to Predict Tumor Recurrence After Stereotactic Radiosurgery for Brain Metastasis. Lee DH; Park JE; Kim N; Park SY; Kim YH; Cho YH; Kim JH; Kim HS Korean J Radiol; 2023 Mar; 24(3):235-246. PubMed ID: 36788768 [TBL] [Abstract][Full Text] [Related]
10. Hypovascular Cellular Tumor in Primary Central Nervous System Lymphoma is Associated with Treatment Resistance: Tumor Habitat Analysis Using Physiologic MRI. Jeong SY; Park JE; Kim N; Kim HS AJNR Am J Neuroradiol; 2022 Jan; 43(1):40-47. PubMed ID: 34824097 [TBL] [Abstract][Full Text] [Related]
11. Clinical Value of Vascular Permeability Estimates Using Dynamic Susceptibility Contrast MRI: Improved Diagnostic Performance in Distinguishing Hypervascular Primary CNS Lymphoma from Glioblastoma. Lee B; Park JE; Bjørnerud A; Kim JH; Lee JY; Kim HS AJNR Am J Neuroradiol; 2018 Aug; 39(8):1415-1422. PubMed ID: 30026384 [TBL] [Abstract][Full Text] [Related]
12. Multiparametric MRI as a potential surrogate endpoint for decision-making in early treatment response following concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma: a systematic review and meta-analysis. Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ Eur Radiol; 2018 Jun; 28(6):2628-2638. PubMed ID: 29374321 [TBL] [Abstract][Full Text] [Related]
13. Do Habitat MRI and Fractal Analysis Help Distinguish Triple-Negative Breast Cancer From Non-Triple-Negative Breast Carcinoma. Xu R; Yu D; Luo P; Li X; Jiang L; Chang S; Li G Can Assoc Radiol J; 2024 Aug; 75(3):584-592. PubMed ID: 38389194 [No Abstract] [Full Text] [Related]
14. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial. Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434 [TBL] [Abstract][Full Text] [Related]
15. Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas. de Godoy LL; Mohan S; Wang S; Nasrallah MP; Sakai Y; O'Rourke DM; Bagley S; Desai A; Loevner LA; Poptani H; Chawla S J Transl Med; 2023 Apr; 21(1):287. PubMed ID: 37118754 [TBL] [Abstract][Full Text] [Related]
16. Deep Learning Segmentation of Infiltrative and Enhancing Cellular Tumor at Pre- and Posttreatment Multishell Diffusion MRI of Glioblastoma. Gagnon L; Gupta D; Mastorakos G; White N; Goodwill V; McDonald CR; Beaumont T; Conlin C; Seibert TM; Nguyen U; Hattangadi-Gluth J; Kesari S; Schulte JD; Piccioni D; Schmainda KM; Farid N; Dale AM; Rudie JD Radiol Artif Intell; 2024 Sep; 6(5):e230489. PubMed ID: 39166970 [TBL] [Abstract][Full Text] [Related]
17. Multiparametric imaging-based differentiation of lymphoma and glioblastoma: using T1-perfusion, diffusion, and susceptibility-weighted MRI. Saini J; Kumar Gupta P; Awasthi A; Pandey CM; Singh A; Patir R; Ahlawat S; Sadashiva N; Mahadevan A; Kumar Gupta R Clin Radiol; 2018 Nov; 73(11):986.e7-986.e15. PubMed ID: 30197047 [TBL] [Abstract][Full Text] [Related]
18. Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model. de Godoy LL; Chawla S; Brem S; Wang S; O'Rourke DM; Nasrallah MP; Desai A; Loevner LA; Liau LM; Mohan S J Neurooncol; 2023 May; 163(1):173-183. PubMed ID: 37129737 [TBL] [Abstract][Full Text] [Related]
19. Prediction of survival and progression in glioblastoma patients using temporal perfusion changes during radiochemotherapy. Larsson C; Groote I; Vardal J; Kleppestø M; Odland A; Brandal P; Due-Tønnessen P; Holme SS; Hope TR; Meling TR; Fosse E; Emblem KE; Bjørnerud A Magn Reson Imaging; 2020 May; 68():106-112. PubMed ID: 32004711 [TBL] [Abstract][Full Text] [Related]